- Home
- PRQR vs EDIT Comparison
PRQR vs EDIT Comparison
Compare PRQR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- EDIT
- Stock Information
- Founded
- PRQR 2012
- EDIT 2013
- Country
- PRQR Netherlands
- EDIT United States
- Employees
- PRQR N/A
- EDIT N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRQR Health Care
- EDIT Health Care
- Exchange
- PRQR Nasdaq
- EDIT Nasdaq
- Market Cap
- PRQR 232.8M
- EDIT 263.7M
- IPO Year
- PRQR 2014
- EDIT 2016
- Fundamental
- Price
- PRQR $2.25
- EDIT $2.57
- Analyst Decision
- PRQR Strong Buy
- EDIT Buy
- Analyst Count
- PRQR 8
- EDIT 12
- Target Price
- PRQR $8.88
- EDIT $5.40
- AVG Volume (30 Days)
- PRQR 319.5K
- EDIT 1.7M
- Earning Date
- PRQR 08-07-2025
- EDIT 08-12-2025
- Dividend Yield
- PRQR N/A
- EDIT N/A
- EPS Growth
- PRQR N/A
- EDIT N/A
- EPS
- PRQR N/A
- EDIT N/A
- Revenue
- PRQR $20,129,184.00
- EDIT $38,901,000.00
- Revenue This Year
- PRQR N/A
- EDIT N/A
- Revenue Next Year
- PRQR N/A
- EDIT N/A
- P/E Ratio
- PRQR N/A
- EDIT N/A
- Revenue Growth
- PRQR 8.65
- EDIT N/A
- 52 Week Low
- PRQR $1.07
- EDIT $0.91
- 52 Week High
- PRQR $4.62
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- PRQR 57.03
- EDIT 46.57
- Support Level
- PRQR $2.18
- EDIT $2.66
- Resistance Level
- PRQR $2.33
- EDIT $2.78
- Average True Range (ATR)
- PRQR 0.13
- EDIT 0.22
- MACD
- PRQR 0.02
- EDIT -0.02
- Stochastic Oscillator
- PRQR 84.91
- EDIT 39.39
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.